Phenylephrini Hydrochloridum (Neosynephrine) Veterinary Grade API is the hydrochloride salt of (R)-3-hydroxy-α-[(methylamino)methyl]benzenemethanol, C₉H₁₃NO₂·HCl, with relative molecular mass 203.67 g/mol. It is supplied as a white or almost white crystalline powder and is controlled against the current Ph. Eur. 0635 and USP Phenylephrine Hydrochloride monographs. The veterinary-grade designation refers not to a different chemical entity but to a release and documentation profile aligned with ICH Q7 for active pharmaceutical ingredients, ICH Q3C residual solvent limits, ICH Q3D elemental impurity limits, and veterinary downstream stability expectations under VICH guidance. The API is used to manufacture tablets, injectable solutions, capsules, powders, granules, premixes, and ophthalmic or nasal solutions for species-specific veterinary indications. The assay window is 98.5–101.0% (dried basis) and loss on drying is ≤ 0.5% by Ph. Eur. 2.2.32. The substance is freely soluble in water, which supports liquid dosage development, but it requires protection from light and oxygen during processing.

Analytical release is structured as a monograph matrix rather than a single assay value. Specific optical rotation is controlled at −42.0° to −47.0° (dried basis, c=2 in water) under Ph. Eur. 2.2.7 to confirm enantiomeric identity. Chloride identification is performed according to Ph. Eur. 2.3.1, and infrared absorption identity is compared against a reference spectrum under Ph. Eur. 2.2.24. Packaging is double food-grade LDPE liners inside a 25 kg HDPE drum with storage below 25 °C and protection from light. The compendial grade for parenteral use requires additional bacterial endotoxin testing under Ph. Eur. 2.6.14, with limits assigned by the downstream injectable monograph.

When Aseptic Filtration Replaces Terminal Sterilization in Injectable Phenylephrine Hydrochloride

Injectable-grade Phenylephrini Hydrochloridum is formulated in aqueous vehicles buffered to pH 3.0–5.0. The compound is freely soluble in water; however, the dissolved form is sensitive to light and oxidative degradation, particularly in the presence of dissolved oxygen and polyvalent metal ions. Manufacturing lines therefore use 316L stainless-steel vessels and nitrogen sparging to reduce dissolved oxygen below 0.5 mg/L. Aseptic filtration through 0.22 µm polyethersulfone or PVDF capsule filters is common because terminal moist-heat sterilization can raise related substance levels. Batch records must document oxygen exposure, temperature excursions, and hold times. Ph. Eur. 2.6.14 bacterial endotoxin testing is applied for injectable intermediates. The selection of 0.22 µm filtration over terminal sterilization is driven by degradation kinetics rather than filter compatibility. Forced-degradation studies at 80 °C and 80% RH often show increased unspecified impurities within 5 days unless antioxidants such as sodium metabisulfite are present; published data for this specific veterinary configuration is limited, so each formulation must be validated under ICH/VICH bracketing conditions.

Production-scale preparation of phenylephrine hydrochloride injection concentrate is typically conducted in jacketed glass-lined or 316L stainless-steel vessels with bottom-mounted magnetic agitators. Because the API is light-sensitive, amber glass or light-protected sampling ports are specified. Final pH adjustment with hydrochloric acid or sodium hydroxide must be performed after the antioxidant is dissolved but before final volume adjustment, because bisulfite partitioning is pH-dependent. A holding-time study under normal room lighting should be included in the process validation protocol; if a visible color shift from clear to pale yellow is detected before 24 hours, the light-protection strategy is inadequate. These operational boundaries are significant for veterinary contract manufacturers preparing small-volume parenterals where dedicated amber filling lines may not be available.

Tablet, Capsule, and Oral Powder Processing Windows

For solid oral dosage forms, the API is typically dry-mixed at 0.1–10% of the total core weight, depending on the target dose and species. Direct compression is feasible when the particle size distribution is controlled to D90 ≤ 150 µm and bulk density is maintained between 0.40 g/mL and 0.60 g/mL, allowing consistent die fill on rotary tablet presses at 30–80 rpm. Wet granulation can be used with purified water or 5–10% w/w povidone binder solution; however, the granulation endpoint must avoid prolonged exposure to temperatures above 60 °C during fluid-bed drying because the hydrochloride salt can darken if local overheating occurs. Magnesium stearate at 0.5–1.0% is used as lubricant; blending times longer than 5–10 minutes may reduce tablet tensile strength due to hydrophobic film formation. Dissolution testing is performed according to Ph. Eur. 2.9.3 or USP <711> with 0.1 M hydrochloric acid or pH 6.8 phosphate buffer, depending on the formulation type.

A production-scale bottleneck observed with this API is segregation in low-dose tablets during direct compression when the API exhibits a large particle-size mismatch with excipients. To manage this, the API can be pre-blended with microcrystalline cellulose at a 1:5 ratio, passed through a 500 µm screen, and then layered into a V-blender with the remaining diluent. This geometric dilution process improves blend uniformity, usually achieving relative standard deviation below 3% across 10 sampling points. For capsule filling, the same pre-mix can be filled on a dosator machine with 0.5% colloidal silicon dioxide added as a glidant. Powder and granule intermediates for sachets or oral solutions should be packaged in foil laminate because the API is hygroscopic under elevated relative humidity; exposure at 75% RH can increase moisture uptake and reduce chemical stability.

For medicated feed premixes and drinking-water formulations, the API is dry-mixed onto a carrier such as lactose monohydrate or dextrose at concentrations of 0.05–2.0% w/w. The carrier blend is normally milled to 250–500 µm before mixing to reduce segregation. A horizontal ribbon blender with 10–20 minutes mixing at 20–30 rpm is often used for pilot-scale batches, followed by assay verification at the top, middle, and bottom of the blender. Liquid concentrate intended for dilution in drinking water is prepared as a preservative-free stock solution at pH 4.0–5.0 and must be protected from light; once diluted in chlorinated drinking water, the API may undergo oxidative degradation if free chlorine exceeds 0.5 ppm. This is a practical incompatibility that field trials must address.

Granules produced by wet granulation for sachets or feed premix may be dried to loss on drying ≤ 2.0% and are typically screened to 850–1400 µm. The granulated form can reduce dust and improve handling in veterinary clinics, but the granulate must be re-analyzed for particle size and assay after terminal drying. Process analytical technology can be used to monitor moisture content; near-infrared probes calibrated with Karl Fischer data under Ph. Eur. 2.5.12 provide real-time release data in some commercial lines.

Does the Veterinary-Grade Salt Form Change the Oxidative Degradation Profile?

The oxidative degradation profile of phenylephrine hydrochloride is governed primarily by the phenolic group, not by the salt form. In acidic solution below pH 5.0, the protonated amino group reduces the rate of autoxidation, but light and trace iron or copper can still generate quinone-like chromophores. The hydrochloride salt is preferentially used for oral and injectable formulations because it has high aqueous solubility and acceptable compatibility with common buffers. The difference from other salt forms is mainly physical: the hydrochloride has a lower relative molecular mass than the bitartrate salt, so equivalent doses require less salt mass. This does not alter the oxidative mechanism but affects the excipient-to-API ratio in low-dose formulations.

Forced-degradation data for phenylephrine hydrochloride in aqueous media typically show pH-dependent degradation with minimum degradation at pH 3.0–4.5; above pH 6.0, the oxidation rate increases markedly. This pH window is therefore specified for parenteral and ophthalmic solutions. The addition of sodium metabisulfite at 0.05–0.2% reduces oxygen-mediated degradation but can cause sulfite sensitivity in some veterinary patients if used in injectable products. An alternative is nitrogen purging plus disodium edetate at 0.01–0.05% as a metal chelator. These formulation choices must be documented in the veterinary product file.

Differences in Clinical Effect Compared with Norepinephrine and Epinephrine in Veterinary Anesthesia

In contrast to norepinephrine hydrochloride, which is typically restricted to continuous intravenous infusion in critical care, phenylephrine hydrochloride is used as a bolus or infusion and can be formulated into non-sterile oral and topical products. The absence of significant β1 chronotropic action at therapeutic concentrations reduces the incidence of tachyarrhythmia in anesthetic protocols, but it also means that phenylephrine does not provide the cardiac output support that norepinephrine can in septic or hypovolemic states. In veterinary anesthesia, phenylephrine is therefore selected for α1-mediated vasopressor support during general anesthesia, while epinephrine remains the injection of choice for cardiac resuscitation. Oxymetazoline, another α agonist, is limited to topical decongestant use and has longer tissue residence. The regulatory dossier for veterinary-grade phenylephrine must document that no human-specific excipient or contaminant profile is assumed; species-specific safety data and residue depletion studies are part of the veterinary drug file.